

Giampaolo Tortora

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11558356/giampaolo-tortora-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

12,651
citations

35
h-index

83
g-index

83
ext. papers

15,027
ext. citations

10.2
avg, IF

5.77
L-index

#	Paper	IF	Citations
78	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016 , 531, 47-52	50.4	1785
77	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015 , 518, 495-501	50.4	1579
76	EGFR antagonists in cancer treatment. <i>New England Journal of Medicine</i> , 2008 , 358, 1160-74	59.2	1570
75	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012 , 491, 399-405	50.4	1427
74	Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 317-327	59.2	826
73	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017 , 543, 65-71	50.4	482
72	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013 , 45, 1470-1473	36.3	464
71	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. <i>Cancer Research</i> , 2002 , 62, 7284-90	10.1	425
70	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018 , 4, 1543-1552	13.4	380
69	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015 , 10, e0130142	3.7	339
68	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 3438-44	12.9	313
67	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2004 , 10, 784-93	12.9	309
66	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 4741-8	12.9	271
65	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. <i>Clinical Cancer Research</i> , 2003 , 9, 1546-56	12.9	229
64	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193
63	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014 , 5, 2839-52	3.3	134
62	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017 , 152, 68-74.e2	13.3	130

61	Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. <i>Clinical Cancer Research</i> , 2008 , 14, 5069-80	12.9	127
60	Key cancer cell signal transduction pathways as therapeutic targets. <i>European Journal of Cancer</i> , 2006 , 42, 290-4	7.5	118
59	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 521-30		94
58	Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. <i>Clinical Cancer Research</i> , 2005 , 11, 5639-44	12.9	79
57	Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 577-83	12.9	75
56	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013 , 4, 56	5.6	66
55	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007 , 75, 788-99	3.5	65
54	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007 , 10, 81-100	23.2	62
53	Angiogenesis: a target for cancer therapy. <i>Current Pharmaceutical Design</i> , 2004 , 10, 11-26	3.3	61
52	Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. <i>Cancer Research</i> , 2007 , 67, 6351-9	10.1	59
51	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12468-73	11.5	56
50	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006 , 208, 344-53	7	54
49	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. <i>Endocrine-Related Cancer</i> , 2011 , 18, 1-11	5.7	52
48	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 200-11	7	50
47	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. <i>Clinical Prostate Cancer</i> , 2003 , 2, 50-7		49
46	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1651-1661	8.9	44
45	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 6531-41	12.9	42
44	Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. <i>International Journal of Cancer</i> , 1993 , 53, 438-43	7.5	41

43	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016 , 21, 283-91	5.7	35
42	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1564-S1580	2.6	35
41	Reporting tumor molecular heterogeneity in histopathological diagnosis. <i>PLoS ONE</i> , 2014 , 9, e104979	3.7	34
40	A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. <i>Clinical Cancer Research</i> , 2009 , 15, 6921-30	12.9	32
39	Antisense strategies targeting protein kinase C: preclinical and clinical development. <i>Seminars in Oncology</i> , 2003 , 30, 26-31	5.5	32
38	High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. <i>BMC Cancer</i> , 2014 , 14, 851	4.8	30
37	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12, 1051-8	5.7	30
36	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008 , 216, 698-707	7	29
35	Rationale and clinical use of multitargeting anticancer agents. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 536-42	5.1	27
34	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2018 , 8, 7119	4.9	25
33	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 535-49	4.1	22
32	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015 , 4, 721-7	4.4	22
31	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019 , 2019, 7652014	4.3	21
30	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody. <i>Proteomics</i> , 2013 , 13, 866-77	4.8	20
29	Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1002, 236-43	6.5	20
28	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 1055-1069	3.8	19
27	Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. <i>Journal of Biological Chemistry</i> , 2010 , 285, 6563-72	5.4	19
26	EGFR-targeting agents in oncology. <i>Expert Opinion on Therapeutic Patents</i> , 2008 , 18, 889-901	6.8	16

25	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , 2019 , 9, 12286	4.9	15
24	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 161-175	3.5	12
23	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 135-45	7	11
22	True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. <i>PLoS ONE</i> , 2012 , 7, e49689	3.7	10
21	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 3091-100	6.1	9
20	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015 , 4, 704-12	4.4	7
19	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
18	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 1381-97	6.2	6
17	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 308	5.7	5
16	Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. <i>Cancer Discovery</i> , 2016 , 6, 821-3	24.4	5
15	Mechanisms of resistance to EGFR inhibitors. <i>Targeted Oncology</i> , 2007 , 2, 31-37	5	5
14	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021 , 152, 155-164	7.5	5
13	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 921-930	3.8	5
12	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , 2019 , 79, 4315-4323	4.3	4
11	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 2021 , 9,		4
10	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 449-455	2.1	3
9	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 567289	5.3	3
8	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , 2018 , 45, 176-180	5.5	3

7	Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response.. <i>Frontiers in Medicine</i> , 2021 , 8, 793144	4.9	1
6	A Novel Pathogenic Variant in an Italian Woman with Gallbladder Cancer. <i>Genes</i> , 2021 , 12,	4.2	0
5	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 117-126	0.4	
4	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 276-283	0.4	
3	EGFR-Directed Monoclonal Antibodies 2010 , 407-436		
2	Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 349-349	2.2	
1	Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS407-TPS407	2.2	